Soligenix Inc. (NASDAQ:SNGX – Get Free Report) saw a significant decrease in short interest in October. As of October 30th, there was short interest totaling 66,373 shares, a decrease of 59.3% from the October 15th total of 162,935 shares. Approximately 0.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 90,729 shares, the short-interest ratio is presently 0.7 days.
Soligenix Trading Down 10.2%
NASDAQ:SNGX traded down $0.03 during mid-day trading on Monday, hitting $0.29. 694,865 shares of the company’s stock were exchanged, compared to its average volume of 2,292,316. The company has a 50 day simple moving average of $0.36 and a 200-day simple moving average of $0.64. Soligenix has a fifty-two week low of $0.27 and a fifty-two week high of $1.70. The firm has a market capitalization of $6.73 million, a P/E ratio of -0.64 and a beta of 2.04.
Soligenix (NASDAQ:SNGX – Get Free Report) last released its quarterly earnings results on Friday, November 6th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.05. As a group, analysts expect that Soligenix will post -0.55 earnings per share for the current year.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Soligenix in a report on Thursday, October 15th. One research analyst has rated the stock with a Sell rating. According to MarketBeat, the stock presently has a consensus rating of “Sell”.
View Our Latest Stock Analysis on Soligenix
About Soligenix
Soligenix, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare diseases and other serious medical conditions. Its work spans therapeutic programs for inflammatory and immunological disorders, as well as vaccine and medical countermeasure development. The company’s BioTherapeutics programs include HyBryte (SGX301), a topical treatment based on synthetic hypericin being developed for cutaneous T-cell lymphoma, and dusquetide (SGX942), which has been studied for oral mucositis associated with cancer treatment.
Featured Stories
- Five stocks we like better than Soligenix
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.
